Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.verified

ADVM

Price:

$8.17

Market Cap:

$169.58M

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorpor...[Read more]

Industry

Biotechnology

IPO Date

2014-07-31

Stock Exchange

NASDAQ

Ticker

ADVM

The Enterprise Value as of July 2024 (TTM) for Adverum Biotechnologies, Inc. (ADVM) is 94.46M

According to Adverum Biotechnologies, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 94.46M. This represents a change of -23.18% compared to the average of 122.97M of the last 4 quarters.

Adverum Biotechnologies, Inc. (ADVM) Historical Enterprise Value (quarterly & annually)

How has ADVM Enterprise Value performed in the past?

The mean historical Enterprise Value of Adverum Biotechnologies, Inc. over the last ten years is 2.04B. The current 94.46M Enterprise Value has changed 363.75% with respect to the historical average. Over the past ten years (40 quarters), ADVM's Enterprise Value was at its highest in in the June 2020 quarter at 16.76B. The Enterprise Value was at its lowest in in the December 2023 quarter at 76.25M.

Quarterly (TTM)
Annual

Average

2.04B

Median

860.12M

Minimum

75.96M

Maximum

12.13B

Adverum Biotechnologies, Inc. (ADVM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Adverum Biotechnologies, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 108.58%

Maximum Annual Enterprise Value = 12.13B

Minimum Annual Increase = -82.14%

Minimum Annual Enterprise Value = 75.96M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202375.96M-20.83%
202295.94M-60.25%
2021241.35M-72.92%
2020891.27M26.46%
2019704.81M-60.37%
20181.78B22.00%
20171.46B75.84%
2016828.96M-61.74%
20152.17B-82.14%
201412.13B108.58%

Adverum Biotechnologies, Inc. (ADVM) Average Enterprise Value

How has ADVM Enterprise Value performed in the past?

The current Enterprise Value of Adverum Biotechnologies, Inc. (ADVM) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

137.75M

5-year avg

401.86M

10-year avg

2.04B

Adverum Biotechnologies, Inc. (ADVM) Enterprise Value vs. Peers

How is ADVM’s Enterprise Value compared to its peers?

Adverum Biotechnologies, Inc.’s Enterprise Value is less than uniQure N.V. (675.21M), less than Rocket Pharmaceuticals, Inc. (2.06B), less than Rhythm Pharmaceuticals, Inc. (3.08B), less than Solid Biosciences Inc. (223.72M), less than MeiraGTx Holdings plc (253.40M), greater than Aerovate Therapeutics, Inc. (42.96M), greater than Adagene Inc. (23.11M), less than Acrivon Therapeutics, Inc. Common Stock (206.17M), less than Rezolute, Inc. (228.71M), greater than AN2 Therapeutics, Inc. (58.53M), greater than Passage Bio, Inc. (45.18M), less than Absci Corporation (388.01M), greater than Kezar Life Sciences, Inc. (31.13M), greater than Oncternal Therapeutics, Inc. (14.60M), greater than Kodiak Sciences Inc. (83.18M), greater than Galmed Pharmaceuticals Ltd. (248.74K), greater than Affimed N.V. (73.76M), less than Mereo BioPharma Group plc (501.61M), greater than Homology Medicines, Inc. (-103303255.00), less than Stoke Therapeutics, Inc. (535.56M), greater than Atreca, Inc. (-8620212.00), greater than TCR2 Therapeutics Inc. (49.64M),

Build a custom stock screener for Adverum Biotechnologies, Inc. (ADVM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adverum Biotechnologies, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Adverum Biotechnologies, Inc. (ADVM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Adverum Biotechnologies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Adverum Biotechnologies, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Adverum Biotechnologies, Inc. (ADVM)?

What is the 3-year average Enterprise Value for Adverum Biotechnologies, Inc. (ADVM)?

What is the 5-year average Enterprise Value for Adverum Biotechnologies, Inc. (ADVM)?

How does the current Enterprise Value for Adverum Biotechnologies, Inc. (ADVM) compare to its historical average?